Empower Clinic Services, LLC dba Empower Pharmacy
Has Empower Clinic Services, LLC dba Empower Pharmacy received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Empower Clinic Services, LLC dba Empower Pharmacy a warning letter naming semaglutide and tirzepatide, dated Sep 18, 2026, with the FDA subject line “CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug.”
FDA records in this index name Empower Clinic Services, LLC dba Empower Pharmacy on Sep 18, 2026.
- Type named in FDA records
- Not stated
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Sep 18, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Sep 18, 2026 | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Sep 18, 2026: … including TIRZEPATIDE/NIACINAMIDE (4 ML)(17/2 MG/ML), SEMAGLUTIDE /CYANOCOBALAMIN (1 ML)(5/0.5 MG/ML), and … which appear to be essentially copies of FDA-approved semaglutide and tirzepatide products. 3, 4 FDA is aware of high demand for compounded versions of FDA-approved semaglutide and tirzepatide products. The volume of products … Full letter
Drug recalls
No openFDA drug recall reports in this index.
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists 2 facilities under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503B)
9 listed actions, including 4 Form 483s, 2 warning letters and 1 untitled letter (2019 to 2025).
| Document | |||
|---|---|---|---|
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 2, 2025 | Warning letter | Warning Letter Issued 04/02/2025 | FDA copy (archived) |
| Aug 28, 2024 | Form 483 | 483 Issued 08/28/2024 | FDA copy (archived) |
| May 4, 2023 | Regulatory meeting | Regulatory Meeting Held 05/04/2023 | Not linked by FDA |
| Aug 5, 2022 | Form 483 | 483 Issued 08/05/2022 | FDA copy (archived) |
| Oct 15, 2021 | Warning letter | Warning Letter (10/15/2021) | FDA copy (archived) |
| Mar 6, 2020 | Form 483 | 483 Issued 03/06/2020 | FDA copy (archived) |
| Jul 22, 2019 | Untitled letter | Untitled Letter Issued 07/22/2019 | FDA copy (archived) |
| Apr 2, 2019 | FMD-145 letter | FMD-145 Letter Issued 04/02/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503A)
5 listed actions, including 3 Form 483s and 2 warning letters (2023 to 2026).
| Document | |||
|---|---|---|---|
| Sep 18, 2026 | Warning letter | Warning Letter Issued 09/18/2026 | fda.gov |
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 2, 2025 | Warning letter | Warning Letter Issued 04/02/2025 | fda.gov |
| Oct 4, 2024 | Form 483 | 483 Issued 10/04/2024 | FDA copy (archived) |
| Dec 1, 2023 | Form 483 | 483 Issued 12/01/2023 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Empower Pharmacy (Empower Clinic Services, LLC), Houston, TX.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Sep 18, 2026
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.